Arcutis Biotherapeutics
ARQT
24.17
+0.25
+1.05%
Arcutis Biotherapeutics
US · ARQT
#2465 by market cap
Listed 2020
24.17
+0.25
+1.05%
Live - 5344 symbols - heartbeat 547s ago
· 2026-10-08 07:15
Pre-market
24.22
+0.21%
After-hours
24.17
0.00%
- Market cap
- 3.04B
- P/E (TTM)i
- 109.86
- P/Bi
- 13.77
- EPSi
- -0.13
- Div yieldi
- 0.00%
- 52W posi
- 39%
Reader sentiment
Are you bullish or bearish on ARQT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.36, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +91.34% YoY
Margins
- Gross margin
- 90.24%
- Operating margin
- -3.25%
- Net margin
- -4.29%
Key ratios & quality
- Enterprise valuei
- 2.93B
- Altman Z-Scorei
- 5.36
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | 0 | 0 | 3.69M | 59.61M | 196.54M | 376.07M |
| Gross profit | -- | -- | 0 | 0 | 2.93M | 54.62M | 177.41M | 339.38M |
| Selling & admin expenses | 1.80M | 6.61M | 21.34M | 60.97M | 122.12M | 185.15M | 229.39M | 274.55M |
| Research & development | 17.94M | 36.52M | 115.31M | 145.56M | 182.44M | 110.58M | 76.42M | 77.05M |
| Operating profit | -19.74M | -43.13M | -136.65M | -206.53M | -301.63M | -241.10M | -128.40M | -12.23M |
| Pretax profit | -19.26M | -42.00M | -135.68M | -206.36M | -311.46M | -259.03M | -139.39M | -14.97M |
| Tax | -- | -- | -- | 0 | 0 | 3.11M | 647.00K | 1.17M |
| Net profit | -19.26M | -42.00M | -135.68M | -206.36M | -311.46M | -262.14M | -140.04M | -16.14M |
| Basic EPS | -1 | -1 | -4 | -4 | -6 | -4 | -1 | 0 |
| Diluted EPS | -1.07 | -1.20 | -3.80 | -4.18 | -5.66 | -3.78 | -1.16 | -0.13 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 65.85M | 81.50M | 99.22M | 129.50M | 105.40M | 129.86M |
| Gross profit | 57.02M | 74.01M | 90.53M | 117.82M | 95.61M | 118.92M |
| Selling & admin expenses | 64.00M | 69.17M | 62.40M | 78.98M | 74.08M | 82.14M |
| Research & development | 17.54M | 19.45M | 19.60M | 20.45M | 30.63M | 20.36M |
| Operating profit | -24.53M | -14.61M | 8.53M | 18.39M | -9.09M | 16.43M |
| Pretax profit | -24.78M | -15.54M | 7.49M | 17.87M | -11.20M | 15.15M |
| Tax | 279.00K | 342.00K | 80.00K | 470.00K | 93.00K | 136.00K |
| Net profit | -25.06M | -15.89M | 7.41M | 17.40M | -11.30M | 15.01M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.20 | -0.13 | 0.06 | 0.13 | -0.09 | 0.11 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 51.10M | 106.47M | 292.83M | 402.77M | 437.41M | 330.43M | 335.82M | 411.23M |
| Cash & ST investments | 50.94M | 101.27M | 284.44M | 387.06M | 409.59M | 271.86M | 227.96M | 220.98M |
| Inventory | -- | -- | -- | 0 | 7.51M | 13.13M | 14.53M | 22.63M |
| Total assets | 51.10M | 107.01M | 298.27M | 408.15M | 449.27M | 341.37M | 348.89M | 432.97M |
| Total current liabilities | 2.67M | 5.24M | 22.60M | 33.33M | 37.81M | 46.67M | 81.01M | 129.84M |
| Short-term debt | -- | 178.00K | -- | 433.00K | 657.00K | 735.00K | -- | 1.00M |
| Long-term debt | -- | -- | -- | 72.35M | 197.77M | 201.80M | 107.20M | 107.96M |
| Total liabilities | 75,085,000.00 | 172,041,000.00 | 27,648,000.00 | 110,475,000.00 | 239,693,000.00 | 252,698,000.00 | 191,348,000.00 | 243,494,000.00 |
| Total equity | -23.99M | -65.03M | 270.62M | 297.68M | 209.58M | 88.67M | 157.54M | 189.48M |
| Retained earnings | -24.28M | -66.27M | -201.95M | -408.31M | -719.76M | -981.90M | -1.12B | -1.14B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 323.67M | 332.78M | 349.22M | 411.23M | 438.06M | 467.67M |
| Cash & ST investments | 198.09M | 190.82M | 191.07M | 220.98M | 224.00M | 238.55M |
| Inventory | 16.61M | 16.32M | 22.42M | 22.63M | 37.39M | 38.88M |
| Total assets | 344.11M | 352.43M | 370.98M | 432.97M | 460.00M | 488.54M |
| Total current liabilities | 91.13M | 103.94M | 99.77M | 129.84M | 163.20M | 160.34M |
| Short-term debt | 842.00K | 1.00M | 1.00M | 1.00M | 7.95M | 6.95M |
| Long-term debt | 107.62M | 107.05M | 107.50M | 107.96M | 101.47M | 101.95M |
| Total liabilities | 201,447,000.00 | 213,459,000.00 | 212,904,000.00 | 243,494,000.00 | 270,355,000.00 | 267,958,000.00 |
| Total equity | 142.66M | 138.97M | 158.07M | 189.48M | 189.65M | 220.58M |
| Retained earnings | -1.15B | -1.16B | -1.16B | -1.14B | -1.15B | -1.13B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -14.09M | -42.84M | -113.03M | -174.63M | -257.72M | -247.06M | -112.16M | -5.63M |
| Depreciation & amortization | 0 | 68.00K | 122.00K | 454.00K | 934.00K | 750.00K | 1.96M | 4.67M |
| Free cash flow | -14.09M | -43.13M | -113.35M | -175.62M | -281.00M | -247.49M | -117.30M | -16.31M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 297.00M | 207.49M | 176.05M | 98.90M | 161.68M | 0 |
| Ending cash balance | 39.39M | 63.34M | 66.62M | 97.99M | 54.88M | 89.32M | 71.95M | 43.22M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -30.38M | 324.00K | -1.75M | 26.19M | 2.24M | 12.64M |
| Depreciation & amortization | 2.98M | 563.00K | 562.00K | 563.00K | 562.00K | 563.00K |
| Free cash flow | -30.99M | -9.75M | -1.75M | 26.19M | 2.24M | 12.48M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 53.72M | 73.05M | 47.43M | 43.22M | 35.07M | 34.43M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -131.99 | -72.62 | -122.80 | -175.79 | -113.76 | -9.30 |
| ROA %i | -70.40 | -53.12 | -66.96 | -58.42 | -72.65 | -66.31 | -40.58 | -4.13 |
| ROIC %i | -- | -- | -128.80 | -63.37 | -75.14 | -67.54 | -42.14 | -4.77 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -123.39 | -98.85 |
| EBIT margin %i | -- | -- | -- | -- | -8,025.12 | -384.72 | -57.10 | -0.77 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 19.12 | 20.33 | 12.96 | 12.09 | 11.57 | 7.08 | 4.15 | 3.17 |
| Quick ratioi | 19.06 | 19.36 | 12.61 | 11.61 | 11.06 | 6.38 | 3.72 | 2.83 |
| Debt / assetsi | 0.00 | 0.29 | 1.66 | 19.00 | 45.08 | 60.32 | 31.46 | 26.38 |
| LT debt / equityi | -- | -- | 1.83 | 25.91 | 96.33 | 231.41 | 69.67 | 59.76 |
| Interest coveragei | -- | -- | -- | -- | -18.90 | -7.72 | -4.13 | -0.24 |
| Revenue CAGR (3Y) %i | -- | -- | 0.00 | 0.00 | -- | -- | -- | 367.27 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -70.58 | -57.33 | -28.17 | -9.30 | -1.43 | 15.86 |
| ROA %i | -31.54 | -23.40 | -10.97 | -4.13 | -0.59 | 6.78 |
| ROIC %i | -32.64 | -24.53 | -10.29 | -4.77 | 0.19 | 11.44 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -50.02 | -28.13 | -9.02 | -0.77 | 2.91 | 9.30 |
| FCF / sales %i | -- | -- | -- | -- | 4.07 | 8.44 |
| Current ratioi | 3.55 | 3.20 | 3.50 | 3.17 | 2.68 | 2.92 |
| Quick ratioi | 3.11 | 2.86 | 3.07 | 2.83 | 2.26 | 2.46 |
| Debt / assetsi | 32.20 | 31.26 | 30.67 | 26.38 | 24.93 | 23.36 |
| LT debt / equityi | 77.08 | 78.55 | 71.34 | 59.76 | 56.27 | 48.59 |
| Interest coveragei | -4.70 | -4.07 | -1.96 | -0.24 | 0.90 | 3.12 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- ZORYVE foam is the largest reported line at 51.88% of revenue, across 4 reported segments.
- ZORYVE cream 0.3% follows at 27.20%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
ZORYVE foam51.88%
ZORYVE cream 0.3%27.20%
ZORYVE cream 0.15%18.66%
ZORYVE cream 0.05%2.25%
Quote time 2026-10-08 07:15:25 · For reference only, not investment advice and not tailored to your situation.